

Hepatocellular Carcinoma Pathogenesis,  
Clinical Presentation, And New Modalities  
of Management In Between Viral and Non-  
Viral Hepatitis

*Essay*

*Submitted for partial fulfillment of Master Degree  
in Internal Medicine*

***By***

Tarek Mohammad Tawfik Al-Haddad  
(M.B.B.Ch., Ain Shams University)

***Supervised By***

Prof. Dr. Khaled Hassan Hemeda

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Dr. Marcel William Keddeas

Assistant Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Dr. Inas Al-Khedr Mohammad

Lecturer of Internal Medicine

Faculty of Medicine - Ain Shams University

**Faculty of Medicine**

**Ain-Shams University**

**2011**

سرطان الكبد ، طرق حدوث المرض،  
الأعراض والوسائل الحديثه للتشخيص  
والعلاج بين المرضى المصابين بالالتهاب  
الكبدى الفيروسي  
وغير المصابين به

توطئة لنيل درجة الماجستير فى الأمراض الباطنة

رسالة مقدمة من

الطبيب/ طارق محمد توفيق الحداد

بكالوريوس الطب والجراحة

كلية الطب- جامعة عين شمس

تحت اشراف

الأستاذ الدكتور/ خالد حسن حميدة

أستاذ الأمراض الباطنة

كلية الطب- جامعة عين شمس

دكتورة/مارسيل ويليام قديس

أستاذ مساعد الأمراض الباطنة

كلية الطب- جامعة عين شمس

دكتورة/إيناس الخضر محمد

مدرس الأمراض الباطنة

كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١١

---

## Summary

Hepatocellular carcinoma (HCC) is one of the most common internal malignancies worldwide. It is the fifth most common cancer and the third cause of cancer-related death worldwide.

The incidence of HCC varies widely according to geographic location, with high incidence in sub-Saharan Africa and South East Asia.

Mostly, HCC arises in the setting of chronic liver disease, usually cirrhosis, HCC arising in a previously normal liver accounts for less than 10% of all HCCs.

The most frequent underlying cause of HCC is chronic hepatitis B, the next most common cause is hepatitis C. Other causes that predispose to HCC include alcoholic cirrhosis, NASH, aflatoxin BI and vinyl chloride exposure, hereditary hemochromatosis,  $\alpha$ -1 antitrypsin deficiency, glycogen storage diseases and primary biliary cirrhosis.

Smoking, family history of HCC, and estrogen exposure are also implicated.

Most of the risk factors for HCC induce mutations in DNA and the genome, or facilitate the proliferation of hepatocytes and the fixation of DNA lesions. Different genetic alterations have been described in human HCC, including gain

# *Contents*

<b>Subjects</b>	<b>Page</b>
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the Essay .....</b>	<b>4</b>
<b>Review of literature .....</b>	<b>5</b>
- Epidemiology and Risk Factors of Hepatocellular Carcinoma.....	<b>5</b>
- Clinical Presentation of Hepatocellular Carcinoma .....	<b>37</b>
- Pathologic Aspects of Hepatocellular Carcinoma.....	<b>46</b>
- Molecular Aspects in Pathogenesis of Hepatocellular Carcinoma.....	<b>53</b>
- Prevention Of Hepatocellular Carcinoma.....	<b>65</b>
- Diagnosis of Hepatocellular Carcinoma .....	<b>91</b>
- Treatment of Hepatocellular Carcinoma.....	<b>132</b>
<b>Summary .....</b>	<b>191</b>
<b>References .....</b>	<b>196</b>
<b>Arabic Summary .....</b>	

*List of Tables*

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
<b>Table (1)</b>	Symptoms and signs of hepatocellular carcinoma.	39
<b>Table (2)</b>	Paraneoplastic syndromes associated with HCC.	43

*List of figures*

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
<b>Fig. (1)</b>	Regional variations in the incidence rates of hepatocellular carcinoma categorized by age-adjusted incidence rates	6
<b>Fig. (2)</b>	Molecular model of hepatocarcinogenesis	54
<b>Fig. (3)</b>	Diagnostic algorithm for suspected HCC	97
<b>Fig. (4)</b>	Ultrasound scan showing a small hypoechoic HCC	116
<b>Fig. (5)</b>	Ultrasound-guided biopsy of a hypoechoic liver lesion, with an echogenic biopsy needle seen traversing the target lesion	117
<b>Fig. (6)</b>	Triple-phase contrast-enhanced CT scans showing two foci of HCC in the right hemiliver	122
<b>Fig. (7)</b>	Typical MRI appearance of HCC	126
<b>Fig. (8)</b>	Treatment Algorithm for HCC	190

*List of Abbreviations*

<b><math>^{13}\text{C}</math></b>	Carbon isotope 13
<b><math>^{90}\text{Y}</math></b>	Yttrium-90
<b>AASLD</b>	The American Association for the Study of Liver Diseases
<b>AFBI</b>	Aflatoxin BI
<b>AFP</b>	Alpha Fetoprotein
<b>AFP-L3</b>	Fucosylated Isoform of AFP
<b>AIDS</b>	Acquired Immunodeficiency Syndrome
<b>BCLC</b>	The Barcelona Clinic Liver Cancer
<b>CEUS</b>	Contrast-enhanced Ultrasound
<b>CHB</b>	Chronic Hepatitis B
<b>CI</b>	Confidence Interval
<b>CLIP</b>	The Cancer of the Liver Italian Program
<b>CT</b>	Computed Tomography
<b>D</b>	Dimentional
<b>DCP</b>	Des-Gamma-Carboxy Prothrombin
<b>DNA</b>	Deoxyribonucleic Acid
<b>FDG</b>	2-[18F]fluoro-2-deoxy-D-glucose
<b>FI</b>	Fucosylation Index
<b>HbeAg</b>	Hepatitis B envelop Antigen
<b>HbsAg</b>	Hepatitis B Surface Antigen
<b>HBV</b>	Hepatitis B Virus
<b>HBx</b>	Hepatitis B Virus-encoded x
<b>HCC</b>	Hepatocellular Carcinoma
<b>HCV</b>	Hepatitis C Virus
<b>HFE</b>	Hereditary Hemochromatosis Gene
<b>hTERT</b>	Human Telomerase Reverse Transcriptase

## List of Abbreviations

---

<b>IFN</b>	Interferon
<b>MDCT</b>	Multidetector Computed Tomography
<b>MELD</b>	Model for end-stage Liver Disease
<b>MRI</b>	Magnetic Resonance Imaging
<b>mRNA</b>	Messenger RNA
<b>NASH</b>	Nonalcoholic Steatohepatitis
<b>PAI</b>	Percutaneous Acetic acid Injection
<b>PCR</b>	Polymerase Chain Reaction
<b>PEI</b>	Percutaneous Ethanol Injection
<b>PET</b>	Positron Emission Tomography
<b>PIVKA-II</b>	Protein Induced by Vitamin K Absence or Antagonist II
<b>RFA</b>	Radiofrequency Ablation
<b>RNA</b>	Ribonucleic Acid
<b>SPIO</b>	Superparamagnetic Iron Oxide
<b>T</b>	Time
<b>TACE</b>	Transarterial Chemoembolization
<b>TAE</b>	Transarterial Embolization
<b>TARE</b>	Transarterial Radioembolization
<b>TNM</b>	Tumor-Node-Metastasis
<b>UCSF</b>	The University of California, San Francisco
<b>UNOS</b>	United Network for Organ Sharing
<b>US</b>	Ultrasound



## **Introduction**

Hepatocellular carcinoma (HCC) accounts for 80% to 90% of primary liver cancer. It's a major health problem worldwide with an estimated incidence ranging between 500.000 and 1.000.000 new cases annually (*Leong TY et al., 2005*).

The major risk factors include infection with hepatitis B or C virus, exposure to dietary aflatoxin BI (AFBI), vinyl chloride, alcohol consumption, smoking, and further inflammatory and oxyradical disorders including Wilson disease or hemochromatosis.  $\alpha$  1- antitrypsin deficiency, schistosomiasis, estrogen exposure, and membranous obstruction of inferior vena cava may also be implicated (*David P. Kelsen et al., 2002*).

Many of the risk factors associated with HCC induce necroinflammatory liver disease, which, if allowed for many years, develops into cirrhosis and perhaps HCC. Recent studies have discovered genetic and epigenetic changes involved in the molecular pathogenesis of HCC, including somatic mutations in the p53 tumor suppressor gene. Other contributory mediators of HCC are metabolising enzymes which can either activate or detoxify these carcinogenic risk factors. Currently, many studies are trying to identify specific populations that may be at

risk for HCC based on their metabolic phenotypes (**Frank Staib et al., 2003**).

Clinical presentation of HCC includes weakness, anorexia, weight loss, fever, abdominal pain, a large irregular liver, or an abdominal mass along with ascites. HCCs are vascular, and a bruit may be heard over the liver, or intraabdominal bleeding may occur (**Liovet JM et al., 2003**).

The diagnosis of HCC is typically made by radiological liver imaging in combination with Alphafetoprotein (AFP). There's an agreement that biopsy proof of HCC is not required prior to surgery. Ultrasound is usually the first line investigation for patients with suspected HCC (**David P. Kelsen et al., 2002**).

High resolution triphasic CT scan, MRI with contrast, and multislice CT are used to diagnose HCC and to assess tumor extent. Recently, superparamagnetic iron oxide-enhanced MRI may be used to differentiate well differentiated HCCs from dysplastic nodules, moderately differentiated, or poorly differentiated HCCs (**Jeong- Min Lee et al., 2009**).

Indocyanine green fluorescent imaging enables the highly sensitive identification of small and grossly unidentifiable HCCs in real time, enhancing the accuracy of liver resection and operative staging (**Takeshi Aoki et al., 2008**).

The diagnostic performance of AFP is inadequate, as it's only elevated in 40%- 60% of cases. Alternative serum biomarkers proposed candidates include telomerase (*Oh BK et al., 2008*), Glypican-3. Squamous cell carcinoma Antigen, PIVKAI, and Follistatin (*Gary Beale et al., 2008*).

For years, partial hepatectomy and liver transplantation have been considered as the main curative treatment for HCC. Currently, various local therapies are used, as local ablative therapy (radiofrequency ablation or percutaneous ethanol injection), Transarterial techniques (transarterial embolization, transarterial chemotherapy, transarterial chemo-embolization, transarterial radioembolization) and some forms of extracorporeal energy therapy (*Lau WY, 2002*).

Other treatments include systemic doxorubicin, tyrosine kinase inhibitors, antiangiogenic agents, immunotherapy, and high- intensity focused ultrasound therapy (*Masuzaki R et al., 2008*).

## **Aim of the Essay**

An overview of HCC, epidemiology, pathogenesis, clinical presentation, recent methods of diagnosis, and new treatment modalities, in between viral and non-viral hepatitis.

# **Epidemiology and Risk Factors of Hepatocellular Carcinoma**


## **Introduction**

Hepatocellular carcinoma (HCC) is one of the most common internal malignancies worldwide. It is the fifth most common cancer and the third cause of cancer-related death worldwide (*Zhao J et al., 2011*). HCC accounts for up to 1 million deaths a year and is the third leading cause of cancer deaths worldwide (*Philips GM et al., 2011*).

For all patients, the 1-, 2-, and 3-year HCC-specific survival rates were  $66.5 \pm 5.3\%$ ,  $52.3 \pm 5.9\%$ , and  $39.1 \pm 6.5\%$  respectively, for the elderly and  $66.7 \pm 3.2\%$ ,  $51.7 \pm 3.5\%$ , and  $40.3 \pm 3.6\%$  respectively, for the young age group (*Kozyreva ON et al., 2011*).

## **Geographic Distribution**

The incidence of HCC varies widely according to geographic location. The distribution of HCC also differs among ethnic groups within the same country, and between regions within the same country (*Jemal A et al., 2011*).



**Fig. (1):** Regional variations in the incidence rates of hepatocellular carcinoma categorized by age-adjusted incidence rates (*White DL et al., 2010*).

High incidence regions (more than 15 cases per 100,000 population per year) include sub-Saharan Africa, the People's Republic of China, Hong Kong, and Taiwan. The incidence is 24.2/100,000 in parts of Africa, and the 35.5/100,000 seen in Eastern Asia. Over 40 percent of all cases of HCC occur in the People's Republic of China, which has an annual incidence of 137,000 cases. Japan has one of the highest incidence rates of HCC. The incidence appears to be decreasing in recent years. Intermediate incidence areas include several countries in Eastern and Western Europe, Thailand, Indonesia, Jamaica,

Haiti, New Zealand (Maoris), and Alaska (Eskimos). North and South America, most of Europe, Australia and parts of the Middle East are low incidence areas with fewer than three cases reported per 100,000 population per year. However, the incidence in the United States has increased during the past two decades (*Schwartz and Carithers, 2011*).

## **Risk Factors**

It is unlikely that HCC is due to a single causative agent. More likely, as with other carcinomas, this tumor is the result of a complex interaction between multiple etiological factors and through a multistep mechanism.

### ***Gender***

For almost all countries, males have higher rates of HCC incidence than females, usually with a ratio of 2:1. Higher discrepancies are seen in some European states, for example, Switzerland (male:female: 4:1) and Italy (male:female: 5:1). In the developing world, the rates are more equal (China [3:1], Gambia [2.8:1] and Zimbabwe [2.4:1]). The reasons for this discrepancy are likely to be multifactorial, in part owing to higher rates of HBV and HCV infection in the male population, but also social factors, such as higher alcohol intake and obesity in men. However, testosterone levels have been shown to correlate with HCC risk, so there is probably also an innate risk